Gastrointestinal stromal tumors (GISTs) are the most common sarcomas of the gastrointestinal tract and are characterized by constitutive activation of the KIT or PDGFRA receptor tyrosine kinases. The crude annual incidence of clinically detected GISTs is about ten cases per million in Europe[@b1] and could be higher in East Asia[@b2]. Localized GISTs represent a potentially curable disease if complete resection can be achieved. However, GISTs are associated with a high risk of recurrence and approximately 40--50% of patients with potentially curative resections develop recurrent or metastatic disease[@b3][@b4]. Moreover, many GISTs were unresectable or metastatic at the time of diagnosis. For those patients, imatinib is the primary therapeutic option, as its use is associated with an improved overall survival compared historic control[@b5]. The majority of GISTs are imatinib-sensitive at diagnosis, but during treatment they may acquire mutations in other exons that make them resistant to imatinib. The median progression-free survival (PFS) with imatinib therapy is 18--24 months[@b6]. Resistance can occur within a focal area of tumor which has previously regressed or remained stable, or it may be muti-focal and widespread in several metastatic deposit sites. Resection remains an option for patients with metastatic GISTs. Surgery of residual disease upon best clinical response conveys a survival benefit compared with historical controls in similar patient collectives treated with imatinib alone[@b7]. But in those that develop widespread progression of metastatic disease after imatinib treatment surgical resection is futile[@b8]. The benefits of surgery for focally progressive tumor after imatinib therapy are still in discussion. Some reports have demonstrated that resection of focally progressive disease can prolong survival and is not associated with early morbidity[@b9][@b10]. But not all studies have found resection of focally progressive disease to be of benefit. Mussi[@b7] *et al*. compared patients undergoing resection of GIST masses at best clinical response to imatinib with focal progression, the later was found to have a significantly lower PFS.

Therefore, the aim of this study was to compare the clinical outcomes of combining surgery with TKI treatment to TKI treatment alone in patients with focally progressive GISTs who were initially responsive to imatinib.

Results
=======

Patient characteristics
-----------------------

The baseline characteristics of GISTs in the S and NS groups are described in [Table 1](#t1){ref-type="table"}. The NS group patients were older than S group patients (median age 61 *vs*. 53 years; *p* = 0.039). And the NS group patients included more women (*p* = 0.031). Surgical interventions were described in [Table 1S](#t1){ref-type="table"}. The 30-day postoperative complication rate was 18.4%, including wound infection (4), abscess (2). There were no perioperative deaths.

Survival outcomes
-----------------

Over a median follow-up duration of 26 months (range 8--104 months), the median PFS for the S groups and NS groups were 12 months (95% CI 10.3--13.7 months) and 6 months (95% CI 4.7--7.3 months), respectly, *p* \< 0.001. The median OS for the S group and NS group were 52 months (95% CI 42.0--63.0 months) and 26 months (95% CI 18.3--33.7 months). The long rank test of the difference was at *p* = 0.003, as show in [Fig. 1](#f1){ref-type="fig"}.

Among S group patients, the patients with R0 resection showed a trend of longer PFS compared with the patients with R2 resection (median PFS 33 *vs.* 12months, *p* = 0.006). However, OS was not different according to the outcome of surgery (median OSs in both groups were not reached; *p* = 0.085), as show in [supplementary Fig. 1](#S1){ref-type="supplementary-material"}.

NS group patients generally received systemic therapy with escalation of imatinib dose or other TKIs. Among NS group patients, 6 patients (31.6%, NS-S) were sensitive to the drugs, 13 patients (68.4%, NS-R) were resistant to TKIs. PFS was significantly longer in drug sensitive patients (11 *vs.* 3 months; *p* \< 0.001). OS was also significantly longer in these patients (54 *vs.* 24 months; *p* = 0.018), as show in [Fig. 2](#f2){ref-type="fig"}. The PFS and OS of NS-S group patients won't different from S group patients (PFS: 12 *vs.* 11months, *p* = 0.789; OS: 52 *vs.* 50 months; *p* = 0.949).

Univariate and multivariate analysis of Progression-free survival and Overall survival
--------------------------------------------------------------------------------------

The results of the univariate and multivariate analyses for the PFS and OS outcomes using Cox regression modeling are list in [Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}. Univariate analysis revealed that without peritoneum metastasis and surgery are associated with a longer PFS. And only surgery was associated with a longer OS. On multivariate analysis, surgery is an independent prognostic factor for longer PFS (HR 2.248, 95% CI 1.192--4.238, *p* = 0.012) and OS (HR 3.319, 95% CI 1.320--8.347, *p* = 0.011).

Discussion
==========

The resistance to imatinib is a life-threatening problem for patients with advanced GIST, because of the limited therapeutic strategies available. The rational for surgical resection of a focally progressive GIST lesion is to resect tumor that has gained resistance to TKI agents to stop disease progression. In our study, the PFS and OS were significantly longer for patients treated with surgery. These indicated that better treatment outcome when residual resistant disease had been resected.

There are little research studies about the role of surgery in patients with locally progressive GISTs. Al-Batran *et al*.[@b11] demonstrated that patients with advanced GIST exhibiting focal disease progression during imatinib therapy may benefit from surgical resection. The median PFS was about 11 months. Hasegawa *et al*.[@b9] indicated that surgical interventions in patients with GIST resistant to imatinib therapy are efficacious when complete resections are performed. Mussi *et al*.[@b7] performed a retrospective analysis of 80 metastatic GIST patients who underwent surgery after imatinib. The 2-year postoperative PFS was significantly better in patients with best clinical response. However, the study didn't show the benefit of surgery in local progression patients. All of these studies have presented low-level evidence because of lack of a control cohort of patients. To my knowledge, there has been no direct comparison between TKI therapy versus surgical resection of focally progressive GISTs combined with TKI therapy. In the study, we direct compared the clinical outcomes of combining surgery with TKI treatment to TKI treatment alone in local progressive patients.

Our results show a clear difference regarding PFS between patients who undergo surgery and not undergo surgery. The present report is the first retrospective study including a control group to show the benefits of surgery for local progressive patients. Other co-variables do not have a significant association with PFS in our multivariate analysis. And also our results indicated that surgery could significantly improve the survival of patients with local progression in univariate analysis and multivariate analysis. Most importantly, we did not find evidence that surgical procedures shortened life, as we did not observe surgery-related mortality. So we can consider surgery before switch to higher doses or second line therapies. We also found that there were no significant differences in PFS and OS between TKI sensitivity of patients and surgery of patients with local progression. It may indicate that if higher doses or another TKI was sensitive to the local imatinib-resistant disease, the operation could not be considered.

Concerning limitations of this study, the major problem with respective analysis is the bias in selecting patients. We found that sex and age were unbalanced between groups. We found that the patients were older in NS group. It indicated that older patients were apt to select TKI therapy only. In our study, both sex and age were not related to PFS or OS.

Although the best way to reduce or eliminate selection bias is a randomized controlled trial, such trials always had to be terminated early because of low participant accrual[@b12][@b13]. In the absence of randomized trials, only retrospective analysis can help physicians choose the best option for the patients. Our study supports the decision of treating GIST patients who were locally progression during imatinib therapy with surgery resection of resistant lesions based on its benefit. Especially, surgery resection of local resistant lesions may much more beneficial to the patients who were also resistant to higher doses imatinib or another TKI.

Surgical resection of local progressive lesion after TKI therapy is likely to be beneficial to patients with local recurrent or metastatic GISTs.

Methods
=======

Patients
--------

Between January 2005 and June 2014, a total of 98 patients were proven recurrent or metastatic GISTs who were treated with imatinib at Zhongshan Hospital Fudan University, Shanghai, China. Only patients who achieved a focally progression for more than 6 months following imatinib treatment according to the Response Evaluation Criteria in Solid Tumors (RECIS[@b14]) were included. Informed written consent was obtained from each participating patient. Progression was defined as a 20% increase in measurable lesion size (RECIST criteria), appearance of new lesion, or reappearance of a lesion that initially showed a complete response. Focally progressive disease was diagnosed by the presence of singular GIST lesion with an absolute growth in size on computed tomography (CT) in patients with previous disease responsive to imatinib. A total of 62 patients were histologically diagnosed with focally progressive GIST during the specified period, but 5 patients were excluded because of insufficient clinical data, such as being lost to follow-up. A final cohort of 57 patients was registered for the study, of whom 38 had undergone surgery after imatinib therapy (Group S) and of whom 19 had received treatment with TKI only (Group NS), as show in [supplementary Fig. 2](#S1){ref-type="supplementary-material"}.

The response to TKI was mainly assessed according to the RECIST with CT scans, which were repeated at 2, 4, and 6 months after surgery or starting new TKI therapy method, and then every 3 months thereafter. Baseline evaluations included physical examinations, laboratory tests, chest X-ray, and CT of abdomen/pelvis with or without chest CT.

Survival was calculated from the initiation of higher dose of imatinib (600 mg/d) or sunitinib treatment or the initiation of surgery until death or the last follow-up. PFS was calculated from the initiation of higher dose of imatinib (600 mg/d) or sunitinib treatment or the initiation of surgery until disease progression. The last patient status was done in Jan 2015. Resection was considered complete if the entire gross tumor was removed with negative resection margins (R0 resection), and incomplete resection was defined as the presence of any gross residual tumors (R2 resection) or microscopic tumor in the surgical resection margin (R1 resection).

The study was approved by the ethics committees of Zhongshan Hospital, Fudan University. The methods were carried out in accordance with the approved guideline.

Statistics
----------

Baseline characteristics were compared using the Wilcoxon rank test for continuous variables (age) and χ^2^ test for categorical variables. PFS and overall survival (OS) were analyzed using the Kaplan-Meier method and compared using the log-rank test. The association of relevant clinical prognostic factors with PFS and OS was assessed using Cox proportional hazards regression modeling; the prognostic power of covariates was expressed by calculating hazard ratios (HRs) with 95% confidence intervals (CI). Variables with significance defined by *p* \< 0.5 in the univariate model were included in the multivariate model, and adjusted HR with 95% CIs were calculated. *P* value \< 0.05 was considered statistically significant. Analysis was performed with SPSS17.0 statistical software.
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###### Characteristics of patients with focally progressive gastrointestinal stromal tumors resistant to imatinib therapy with surgery or without surgery.

  Characteristics                    Group S n = 38   Group NS n = 19   *P* value[\*](#t1-fn2){ref-type="fn"}  
  --------------------------------- ---------------- ----------------- --------------------------------------- --------------------------------------
  Age (year)                                                                                                    **0.039[§](#t1-fn2){ref-type="fn"}**
                                         Median             53                           61                                       
                                        (range)          (24--75)                     (37--77)                                    
  Gender                                                                                                                     **0.031**
                                          Male            31 (41)                      10 (41)                                    
                                         Female           7 (16)                       9 (16)                                     
  Primary tumor site                                                                                                           0.829
                                        Stomach           10 (16)                      6 (16)                                     
                                      Small bowel         22 (33)                      11 (33)                                    
                                         Others            6 (8)                        2 (8)                                     
  Cell type                                                                                                                    0.878
                                        Spindle           35 (52)                      17 (52)                                    
                                      Epithelioid          2 (3)                        1 (3)                                     
                                         Mixed             1 (2)                        1 (2)                                     
  Tumor mitotic count per 50 HPFs                                                                                              0.959
                                           ≤5              4 (6)                        2 (6)                                     
                                         6\~10             5 (7)                        2 (7)                                     
                                          \>10            29 (44)                      15 (44)                                    
  Performance status (ECOG)                                                                                                    0.667
                                           0              30 (43)                      13 (43)                                    
                                           1              7 (12)                       5 (12)                                     
                                           2               1 (2)                        1 (2)                                     
  Gene type of primary tumors                                                                                                  0.783
                                        Exon 11           27 (41)                      14 (41)                                    
                                         Exon 9            5 (6)                        1 (6)                                     
                                       Wide type           1 (2)                        1 (2)                                     
                                     Not availiable        5 (8)                        3 (8)                                     
  Site of tumor involvement                                                                                                    0.625
                                         liver            21 (31)                      10 (31)                                    
                                       peritoneum         24 (39)                      15 (39)                                    

HPF, high-power field.

\*χ^2^ test, except ^§^Wilcoxon rank test.

###### Univariate and multivariate analyses for progression-free survival in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib therapy.

                                             PFS                                            
  --------------------------------- --------------------- ----------- --------------------- -----------
  Age (year)                         0.832(0.451--1.532)     0.554                                
  ≥60                                                                                             
  \<60                                                                                            
  Gender                             1.379(0.743--2.559)     0.309     1.312(0.657--2.619)     0.441
  Male                                                                                            
  Female                                                                                          
  Performance status                 1.374(0.729--2.589)     0.325     0.827(0.396--1.728)     0.614
  ECOG                                                                                            
  0                                                                                               
  1/2                                                                                             
  Primary tumor site                 1.551(0.824--2.917)     0.174     1.417(0.685--2.931)     0.347
  Gastric                                                                                         
  Nongastric                                                                                      
  Cell type                          0.829(0.326--2.105)     0.693                                
  Spindle                                                                                         
  Nonspindle                                                                                      
  Tumor mitotic count per 50 HPFs    1.866(0.924--3.769)     0.082     1.552(0.695--3.464)     0.283
  ≤10                                                                                             
  \>10                                                                                            
  KIT mutations.                     0.747(0.311--1.794)     0.515                                
  Exon 11                                                                                         
  Others                                                                                          
  Site of tumor involvement Liver    0.725(0.415--1.267)     0.259     1.169(0.603--2.265)     0.644
  Yes                                                                                             
  No                                                                                              
  **Peritoneum**                     2.028(1.055--3.901)   **0.034**   1.706(0.741--3.929)     0.209
  Yes                                                                                             
  No                                                                                              
  **Group**                          2.615(1.457--4.694)   **0.001**   2.248(1.192--4.238)   **0.012**
  S                                                                                               
  NS                                                                                              

###### Univariate and multivariate analyses for overall survival in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib therapy.

                                              OS                                              
  --------------------------------- ---------------------- ----------- ---------------------- -----------
  Age (year)                         0.521(0.221--1.227)      0.136     0.392(0.146--1.048)      0.062
  ≥60                                                                                               
  \<60                                                                                              
  Gender                             1.325(0.571--3.074)      0.512                                 
  Male                                                                                              
  Female                                                                                            
  Performance status                 1.786(0.828--3.853)      0.139     0.951(0.377--2.402)      0.951
  ECOG                                                                                              
  0                                                                                                 
  1/2                                                                                               
  Primary tumor site                 1.685(0.716--3.970)      0.232     1.310(0.480--3.577)      0.598
  Gastric                                                                                           
  Nongastric                                                                                        
  Cell type                          0.738(0.175--3.109)      0.679                                 
  Spindle                                                                                           
  Nonspindle                                                                                        
  Tumor mitotic count per 50 HPFs    3.869(0.918--16.300)     0.065     2.482(0.529--11.648)     0.249
  ≤10                                                                                               
  \>10                                                                                              
  KIT mutations                      0.698(0.206--2.362)      0.563                                 
  Exon 11                                                                                           
  Others                                                                                            
  Site of tumor involvement Liver    0.706(0.336--1.486)      0.359     0.820(0.369--1.823)      0.627
  Yes                                                                                               
  No                                                                                                
  Peritoneum.                        1.902(0.771--4.687)      0.163     1.211(0.433--3.388)      0.716
  Yes                                                                                               
  No                                                                                                
  Group                               2.329(1.049--5.170    **0.038**   3.319(1.320--8.347)    **0.011**
  S                                                                                                 
  NS                                                                                                

[^1]: These authors contributed equally to this work.
